<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vorapaxar: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vorapaxar: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vorapaxar: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95243" href="/d/html/95243.html" rel="external">see "Vorapaxar: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F24763920"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk: </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Do not use vorapaxar in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage; or active pathological bleeding. Antiplatelet agents, including vorapaxar, increase the risk of bleeding, including intracranial hemorrhage and fatal bleeding.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57646970"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zontivity</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24763922"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Protease-Activated Receptor-1 (PAR-1) Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F24959213"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Vorapaxar 2.08 mg is equivalent to vorapaxar sulfate 2.5 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0f1cb54-bdb8-458e-a179-eaa329719292">History of MI or established peripheral arterial disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>History of MI or established peripheral arterial disease (PAD):</b>
<b>Note: </b> Role in therapy not well established. The overall clinical benefit of adding vorapaxar to other antiplatelet therapy is uncertain; must consider the risk-benefit of bleeding versus reduction in cardiovascular events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27851991','lexi-content-ref-22443427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27851991','lexi-content-ref-22443427'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.08 mg once daily in combination with aspirin and/or clopidogrel; there is no experience with use of vorapaxar as monotherapy or with antiplatelet agents other than aspirin and/or clopidogrel.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992032"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Unknown if dialyzable, but unlikely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989335"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F24959214"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F25017967"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic and oncologic: Hemorrhage (any GUSTO [Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries] bleeding [severe, moderate, mild]): 25%), major hemorrhage, life-threatening (13%; clinically significant bleeding, including any bleeding requiring medical attention such as intracranial hemorrhage, or clinically significant overt signs of hemorrhage associated with a drop in hemoglobin of ≥3 g/dL [or when hemoglobin is unavailable, an absolute drop in hematocrit of ≥15% or a fall in hematocrit of 9% to &lt;15%])</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Depression (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%, includes cutaneous eruptions and exanthemas) </p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Iron deficiency (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic and oncologic: Anemia (5%), major hemorrhage (GUSTO bleeding category “moderate or severe”: 3%; GUSTO bleeding category “severe”: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinopathy (&lt;2%)</p>
<p style="text-indent:0em;">&lt;1%, postmarketing, and/or case reports: Diplopia (or oculomotor disturbance), hemorrhagic death, intracranial hemorrhage </p></div>
<div class="block coi drugH1Div" id="F24763925"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH); active pathological bleeding (eg, ICH, peptic ulcer bleeding)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to vorapaxar or any ingredient in the formulation; severe hepatic impairment</p></div>
<div class="block war drugH1Div" id="F24958246"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: <b>[US Boxed Warning]: Use is contraindicated in patients with history of stroke, TIA, or ICH; or active pathological bleeding. Discontinue use in patients who experience a stroke, TIA, or ICH during therapy. Vorapaxar increases the risk of bleeding, including ICH and fatal bleeding.</b> The risk of bleeding is proportional to the patient's underlying bleeding risk. General risk factors for bleeding include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and concomitant use of medications known to increase the risk of bleeding (eg, anticoagulants, NSAIDS, SSRIs, SNRI); avoid use with anticoagulants. <b>Note:</b> No specific antidote exists for vorapaxar reversal. Significant inhibition of platelet aggregation remains 4 weeks after discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Due to increased risk of bleeding, use is not recommended in patients with severe hepatic impairment; use with caution in patients with mild or moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Due to increased risk of bleeding, use with caution in patients with renal impairment.</p></div>
<div class="block foc drugH1Div" id="F57646971"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zontivity: 2.08 mg</p></div>
<div class="block geq drugH1Div" id="F24887519"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F25211460"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zontivity Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.08 mg (per each): $18.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F24959218"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with or without food.</p></div>
<div class="block meg drugH1Div" id="F28212664"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F92207%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPHSVoL%2BV1ggnJzULZeiu8ySnMPsZqebHsVsv4YzZ0Ev4rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=95242" target="_blank">https://www.fda.gov/media/92207/download</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F24763924"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>History of MI or established peripheral arterial disease:</b> To reduce thrombotic cardiovascular events (cardiovascular death, MI, stroke, urgent coronary revascularization) in patients with a history of MI or with peripheral arterial disease (PAD)</p></div>
<div class="block cyt drugH1Div" id="F24803022"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2J2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F24803006"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Vorapaxar may enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Vorapaxar.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Vorapaxar.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vorapaxar.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vorapaxar.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Vorapaxar.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F24958183"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Due to the potential for serious adverse events (eg, maternal bleeding, hemorrhage) and the long half-life of vorapaxar, alternate agents may be preferred in pregnant women. Discontinue use if pregnancy is detected.</p></div>
<div class="block brc drugH1Div" id="F24958185"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vorapaxar is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for adverse events in a breastfed infant (eg, bleeding), breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F24959220"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of bleeding; hemoglobin and hematocrit periodically</p></div>
<div class="block pha drugH1Div" id="F24958249"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vorapaxar, an antagonist of the protease-activated receptor-1 (PAR-1) expressed on platelets,  inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Due to the very long half-life, vorapaxar is effectively irreversible. Vorapaxar reversibly binds to the PAR-1 receptor with a long receptor dissociation half-life of approximately 20 hours; additionally, vorapaxar displays significant inhibition of platelet aggregation that remains for up to 4 weeks after discontinuation due to the very long elimination half-life (Ueno 2010).</p></div>
<div class="block phk drugH1Div" id="F24958351"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ≥80% inhibition of TRAP-induced platelet aggregation within 1 week</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Dose and concentration dependent; with the recommended dosing, inhibition of TRAP-induced platelet aggregation at a level of 50% can be expected 4 weeks after discontinuation</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly absorbed (Kosoglou 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: ~424 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥99% to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and CYP2J2. Major active metabolite: M20 (accounts for ~20% of exposure to vorapaxar)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~100%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Effective half-life: 3 to 4 days; Terminal elimination half-life (vorapaxar and active metabolite): ~8 days (range: 5 to 13 days)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily in the form of metabolites through feces (58%); urine (25%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45783813"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zontivity</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zontivity</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zontivity</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23501976">
<a name="23501976"></a>Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. <i>Circulation</i>. 2013;127(14):1522-1529, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/23501976/pubmed" id="23501976" target="_blank">23501976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46. doi: 10.1007/s12028-015-0222-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27851991">
<a name="27851991"></a>Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;69(11):1465-1508. doi: 10.1016/j.jacc.2016.11.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/27851991/pubmed" id="27851991" target="_blank">27851991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21935705">
<a name="21935705"></a>Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2012;68(3):249-258. doi: 10.1007/s00228-011-1120-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/21935705/pubmed" id="21935705" target="_blank">21935705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22443427">
<a name="22443427"></a>Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. <i>N Engl J Med</i>. 2012;366(15):1404-1413. doi: 10.1056/NEJMoa1200933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/22443427/pubmed" id="22443427" target="_blank">22443427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NDA.1">
<a name="NDA.1"></a>NDA 294–886. Cross-discipline Team Leader review on Vorapaxar, April 18th, 2014. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf</a>. Assessed May 15, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22932716">
<a name="22932716"></a>Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. <i>Lancet</i>. 2012;380(9850):1317-1324. doi: 10.1016/S0140-6736(12)61269-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/22932716/pubmed" id="22932716" target="_blank">22932716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26340124">
<a name="26340124"></a>Serebruany VL, Fortmann SD. The FDA report on vorapaxar in the elderly: A convoluted dilemma. <i>Int J Cardiol</i>. 2015;201:601-603. doi: 10.1016/j.ijcard.2015.08.177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/26340124/pubmed" id="26340124" target="_blank">26340124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22077816">
<a name="22077816"></a>Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>N Engl J Med</i>. 2012;366(1):20-33. doi: 10.1056/NEJMoa1109719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/22077816/pubmed" id="22077816" target="_blank">22077816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20670195">
<a name="20670195"></a>Ueno M, Ferreiro JL, Angiolillo DJ. Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Rev Cardiovasc Ther</i>. 2010;8(8):1191-1200. doi: 10.1586/erc.10.49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vorapaxar-drug-information/abstract-text/20670195/pubmed" id="20670195" target="_blank">20670195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zontivity.1">
<a name="Zontivity.1"></a>Zontivity (vorapaxar) [prescribing information]. Ridgeland, MS: WraSer Pharmaceuticals; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zontivity.2">
<a name="Zontivity.2"></a>Zontivity (vorapaxar) [product monograph]. Caledon, Ontario, Canada: Regulatory Solutions Inc; October 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 95242 Version 132.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
